Flag of the European Union EU Clinical Trials Register Help

Clinical trials for covid-19

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43841   clinical trials with a EudraCT protocol, of which   7281   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    813 result(s) found for: covid-19. Displaying page 1 of 41.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-000714-33 Sponsor Protocol Number: PT26/17/01 Start Date*: 2023-02-21
    Sponsor Name:tiakis Biotech AG (formerly Proteo Biotech AG)
    Full Title: Efficacy and safety of Tiprelestat for treatment of severe COVID-19 (COMCOVID trial)
    Medical condition: Adult patients with COVID-19 fulfilling the following criteria: -First laboratory-confirmation of the current episode of SARS-CoV-2 infection (COVID-19) as determined by PCR or antigen test (no sel...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001331-26 Sponsor Protocol Number: PROLIFIC2020 Start Date*: 2020-04-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial)
    Medical condition: Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001783-28 Sponsor Protocol Number: BCG-COVID_HU_001 Start Date*: 2020-05-06
    Sponsor Name:National Korányi Institute of Pulmonology
    Full Title: REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION
    Medical condition: healthy volunteers working in the healthcare treating patients with new type of coronavirus (SARS-CoV-2) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004016-26 Sponsor Protocol Number: Clin_COVID-19_Corok Start Date*: 2021-10-18
    Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital
    Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection"
    Medical condition: None
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002445-15 Sponsor Protocol Number: Prevent-COVID Start Date*: 2021-09-27
    Sponsor Name:InfectoPharm Arzneimittel und Consilium GmbH
    Full Title: Placebo-kontrollierte randomisierte doppel-blinde Phase III Studie zur Wirksamkeit und Sicherheit von Ivermectin Tabletten (Driponin®) für die Prophylaxe der COVID-19 Erkrankung bei im Haushalt leb...
    Medical condition: COVID-19 Post-Expositionsprophylaxe
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001590-31 Sponsor Protocol Number: 22/01611 Start Date*: 2022-10-20
    Sponsor Name:Norwegian Institute of Public Health
    Full Title: A parallel group, prevention, phase iv, unblinded 2-arm study to investigate hospital admission and deaths due to COVID-19, after receiving an invitation to take a second booster COVID-19 vaccine c...
    Medical condition: COVID-19.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004788-29 Sponsor Protocol Number: Covid_vacc_THL2021 Start Date*: 2021-12-23
    Sponsor Name:Finnish Institute for Health and Welfare
    Full Title: COVID-19 vaccine immunological studies in Finland
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000627-12 Sponsor Protocol Number: CV43140 Start Date*: 2021-06-01
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) PT (Prematurely Ended) DK (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-001357-31 Sponsor Protocol Number: IIV-478 Start Date*: 2021-05-03
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003547-24 Sponsor Protocol Number: 21CH134 Start Date*: 2021-08-25
    Sponsor Name:CHU de Saint Etienne
    Full Title: Factors influencing the COVID-19 vaccine immune response (reactogenicity and immunogenicity) according to age and presence or not of a past history of COVID-19. COVIMMUNAGE study
    Medical condition: Volunteer
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001993-52 Sponsor Protocol Number: IMCOVAS Start Date*: 2021-05-20
    Sponsor Name:University of Antwerp
    Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc...
    Medical condition: Coronavirus disease-19 (COVID-19)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001610-38 Sponsor Protocol Number: JAGG2020-1 Start Date*: 2020-09-16
    Sponsor Name:Slagelse Sygehus
    Full Title: Irbesartan and Oseltamivir treatment of COVID-19 infection.
    Medical condition: The combined treatment in this trial will be used to treat patients with Covid-19 infection in order to prevent the patients need for further treatment in a hospital.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001251-41 Sponsor Protocol Number: P20/05 Start Date*: 2020-04-17
    Sponsor Name:CH de Versailles
    Full Title: A PROOF OF CONCEPT STUDY TESTING THE VALUE OF IMATINIB IN PREVENTION OF COVID-19 IN AGED PATIENTS.
    Medical condition: Aged patients at risk of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004891-33 Sponsor Protocol Number: T33/2021 Start Date*: 2022-04-13
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000781-15 Sponsor Protocol Number: COVFATI Start Date*: 2021-12-14
    Sponsor Name:Amsterdam UMC VUmc
    Full Title: Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19
    Medical condition: Chronic fatigue after COVID-19 infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005759-18 Sponsor Protocol Number: CV43043 Start Date*: 2021-05-10
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERAT...
    Medical condition: Mild to Moderate coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002327-38 Sponsor Protocol Number: NL77670.029.21 Start Date*: 2021-05-26
    Sponsor Name:Academic Medical Center
    Full Title: PREGCOVAC-19: the follow up of pregnant women who received COVID-19 vaccination in the Dutch national vaccination program
    Medical condition: Pregnant women aged ≥ 18 years who are scheduled for COVID-19 vaccination within the Dutch national vaccination program with any of the currently or future available vaccines that are used for preg...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    21.1 100000004868 10036586 Pregnant LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002098-25 Sponsor Protocol Number: ZKSJ0137_INFLIXCOVID Start Date*: 2021-05-27
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID)
    Medical condition: severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001194-69 Sponsor Protocol Number: MEFLOCOVID-19 Start Date*: 2020-03-30
    Sponsor Name:Félix Gutiérrez Rodero [...]
    1. Félix Gutiérrez Rodero
    2. Mar Masiá Canuto
    Full Title: Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19)
    Medical condition: COVID-19 infection is being spread around the world with more than 400.000 cases. The spred of the disease is being a world health problem.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004419-14 Sponsor Protocol Number: T125/2020 Start Date*: 2021-10-18
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 infections in hospital personnel
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 17 01:43:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA